The Enhancer of Zeste Homolog 2 (EZH2), a catalytic component of Polycomb Repressive Complex 2 (PRC2), which, in turn, is involved in regulating chromatin organization (6), has been identified as a potential therapeutic target for multiple cancers due to its frequent overexpression and role in tumor progression (7). Here, EZH2 is linked to cancer.